Platelet transfusion and respecting patient D type.

Area of Science:

• Hematology
• Immunology
• Transfusion Medicine

Background:

• Current guidelines permit D-mismatched platelet transfusions for D-negative recipients under logistical constraints.
• Platelet concentrates are labeled with D antigen status due to residual red blood cells, despite the D antigen not being on platelets.
• D matching is advised to prevent D alloimmunization, with historical frequencies up to 18.7% in whole blood-derived products.

Purpose of the Study:

• To evaluate the risk of D alloimmunization following D-mismatched platelet transfusions.
• To assess the impact of red blood cell content in different platelet concentrate preparations.
• To provide recommendations for preventing D alloimmunization in at-risk populations.

Main Methods:

• Review of current guidance and recent large retrospective studies.
• Analysis of red blood cell content in pooled whole blood-derived and apheresis platelet concentrates.
• Evaluation of D alloimmunization frequencies in D-negative patients receiving D-mismatched platelets.

Main Results:

• Pooled platelet concentrates from whole blood collections have significantly higher red blood cell content (0.036–0.59 ml) than apheresis products (0.00017–0.009 ml).
• Studies indicate a D alloimmunization frequency ranging from 0% to 7.1% after D-mismatched platelet transfusions.
• Secondary immunization cannot be ruled out in D-negative patients developing alloanti-D within 4 weeks of transfusion.

Conclusions:

• Administering Rh Immune Globulin is recommended when transfusing D-mismatched platelet concentrates from whole blood collections to D-negative females of childbearing potential.
• This recommendation is based on observed D alloimmunization frequencies and findings from recent large-scale studies.
• The risk of D alloimmunization necessitates preventative measures in specific patient groups.